In patients with subclinical atrial fibrillation (SCAF), apixaban reduces stroke risk but increases major gastrointestinal bleeding compared with aspirin , while intracranial and fatal bleeding rates remain comparable. In this ARTESiA subanalysis of 3961 patients followed for 3.5 years , most major bleeds in both treatment arms were non-emergencies , characterized by significant hemoglobin drops rather than critical-site hemorrhage. Major bleeding risk was strongly influenced by NSAID use, cancer, older age, and assignment to apixaban .
Notably, apixaban-related bleeding was less likely to occur at critical sites, supporting its overall safety profile despite the rise in GI events. These insights help refine treatment decisions where stroke prevention must be balanced against bleeding risk. To read more ; Click here How could these bleeding patterns influence your anticoagulation…
